Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 8/20 | 0.43 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.42 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.42 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | SLC43A1 | O75387 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13714166 | 0.94 | LGALS9 (0.46) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL18296432 | 0.94 | LGALS9 (0.46) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL6221505 | 0.94 | LGALS9 (0.46) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL6857875 | 0.94 | LGALS9 (0.46) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL12653015 | 0.94 | LGALS9 (0.46) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL18148952 | 0.94 | LGALS9 (0.46) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL19591662 | 0.94 | LGALS9 (0.46) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL30185438 | 0.93 | LGALS9 (0.47) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL19646640 | 0.85 | TSHR (0.47) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL17682036 | 0.85 | TSHR (0.47) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080008709-A1 | Conjugation of biomolecules using Diels-Alder cycloaddition | The Government of the U.S. as represented by the Secretary of the Dept. of Health and Human | 2008-01-10 | — | — | US | disclosed |
| US-7211445-B2 | Immunology, diagnosis, therapy; complex of carbohydrate and protein; immobilization | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080008709-A1 | Conjugation of biomolecules using Diels-Alder cycloaddition | DERA, DCLRE1A, CD2BP2 | ABCB1 4291/4885LGALS9 2034/4885LGALS1 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.